Recombinant COVID-19 Vaccine Candidate Launches Early-stage Study
Beijing-based YishengBio Co., Ltd announced on July 18, 2021, that it had received IND clearance for PIKA recombinant COVID-19 vaccine to conduct a Phase I clinical trial from the United Arab Emirates Ministry of Health & Prevention.
PIKA recombinant COVID-19 vaccine is a PIKA adjuvanted recombinant trimeric SARS-Cov-2 spike (S) protein subunit vaccine (CHO cells).
Mr. Yi Zhang, YishengBio's chairman and the project leader expressed his enthusiasm in a press release saying, "we are very pleased with this important milestone for PIKA recombinant COVID-19 vaccine."
"Since the outbreak of COVID-19, our research team has designed and optimized several recombinant protein antigen candidates and ultimately selected YS-SC2-010 antigen to move forward after rigorous screening and optimization efforts."
"PIKA adjuvant plays a critical role in the vaccine complex by enhancing both antibody and cellular immunity and ultimately providing a broad and sustainable protective effect."
"Our proprietary PIKA adjuvant technology is based on TLR-3 agonist technology independently developed by our research team and has been granted over 60 patents among more than 30 countries with additional 40 patents in application or review stage."
"PIKA technology has been used in developing a variety of new generation of vaccine candidates, such as PIKA rabies vaccine, PIKA immuno-oncology product, PIKA HBV vaccine, and PIKA influenza vaccine."
"In addition, PIKA adjuvant technology can significantly reduce the dose of antigens used, hence significantly increasing vaccine production and providing vaccines to more countries and regions worldwide, benefiting more people," commented Mr. Yi Zhang.
YishengBio is a biopharmaceutical company focusing on the discovery, development, manufacturing, and commercialization of new generations of vaccines and therapeutic biologics in the field of infectious diseases and cancer.